Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in pediatric patients with relapsed or refractory hematological malignancies

Trial Profile

International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies in children Subprotocol D: Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in pediatric patients with relapsed or refractory hematological malignancies

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Trametinib (Primary) ; Trametinib (Primary)
  • Indications Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms HEM-iSMART Subprotocol D

Most Recent Events

  • 24 May 2023 Planned End Date changed to 11 Nov 2030.
  • 24 May 2023 Status changed from not stated to recruiting.
  • 09 Mar 2023 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top